on POXEL (EPA:POXEL)
Poxel appoints Yves Decadt as its new Chief Executive Officer
On June 10, 2026, Poxel SA, a biopharmaceutical company listed on Euronext Paris, announced the appointment of Yves Decadt as Chief Executive Officer. This decision follows the restructuring period led by Nicolas Trouche. Decadt, who already served on the Board of Directors, will continue implementing the Business Continuity Plan approved in January 2026.
His mission includes the commercial development of Imeglimin in Asia and the development of PXL065 for the treatment of specific metabolic disorders. With 25 years of experience, notably at Johnson & Johnson, Decadt possesses key expertise to guide Poxel toward new partnerships and commercial opportunities.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all POXEL news